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Abstract
Background: Molecular mechanisms of the functional alteration of hematopoietic stem cells (HSCs) in leukemic
environment attract intensive research interests. As known in previous researches, Maff and Egr3 are two important
genes having opposite functions on cell cycle; however, they are both highly expressed in HSCs under leukemia.
Hence, exploring the molecular mechanisms of how the genes act on cell cycle will help revealing the functional
alteration of HSCs.
Results: We herein utilize the bioinformatic resources to computationally model the acting mechanisms of Maff
and Egr3 on cell cycle. Using the data of functional experiments as reference, molecular acting mechanisms are
optimally enumerated through model selection. The results are consolidated by evidences from gene sequence
analysis, thus having enhanced the confidence of our pilot findings, which suggest that HSCs possibly undergo a
“adaptation - suppression” process in response to the malignant environment of leukemia.
Conclusion: As a pilot research, our results may provide valuable insights for further experimental studies. Meanwhile,
our research method combining computational modeling and data from functional experiments can be worthwhile
for knowledge discovery; and it can be generalized and extended to other biological/biomedical studies.
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Background
Maff and Egr3 are two important regulatory factors in
hematopoiesis development. Previous studies showed
that Maff was mainly responsible for the transcription
regulation of megakaryote differentiation (towards plate-
let) [1–3]; and less was known for the functions of Egr3
in cell cycle [4]. Both Maff and Egr3 are able to
recognize certain DNA elements, thus enhancing the
transcriptions of their target genes [5, 6]. We had dem-
onstrated via gene over-expression and in vitro cell cul-
ture in our previous study that Maff stimulated cell cycle
(i.e. pro-proliferation); and Egr3 potently suppressed cell
cycle (i.e. counter-proliferation) [7, 8]. In addition, we
found via molecular profiling that Egr3 up-regulated p18
and p19, two cyclin-dependent kinase inhibitors (CKIs),
which might be how Egr3 suppressed cell cycle [7].
However, we also discovered that both Maff and Egr3
were highly expressed in hematopoietic stem cells
(HSCs) under leukemia (especially at the late stage, i.e. ≥
day 14), in which the cell cycles of most HSCs were
heavily suppressed [7–9]. Therefore, the molecular
mechanisms of how Maff and Egr3 act on cell cycle and
why the two functionally-opposite genes are both highly
expressed under leukemia, remain to be revealed.
Nonetheless, forthcoming experiments with respect to
molecular regulations are preceded by a major concern
that there are usually too many molecular interactions,
outnumbering the experimental capacity. Hence direct
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experimentation is possibly not affordable. Meanwhile,
simplistic a priori computational methods such as hyper-
positioning of static molecular networks, as in most pre-
vious researches, cannot adequately solve the question.
As it is known, cell cycle is governed by the dynamic
states of cyclins and cyclin-dependent kinases (CDKs),
as well as various (positive/negative) regulatory factors.
On the other hand, cell cycle dynamics of many prokary-
otic/eukaryotic organisms are well-understood and
mathematical models are established [10]. Therefore, we
herein conduct a pilot study, using mathematical model-
ing and data of prior experiments to refine/optimize the
possible ways of molecular actions. First, we use infor-
mation of molecular interactions to indicate possible
actions related to Maff/Egr3. Second, we numerically test
the possibilities with experimental data of HSC cell cycle
[7, 8]. The tests are implemented on a curated cell cycle
dynamic model with organism comparability to our ex-
perimental data [11–13], aiming to find out the ways of
actions giving rise to the particular kinetic phenomena
observed in the experiments. And finally, optimal possi-
bilities that pass the tests, i.e. the ways of actions that
should be in place so that the experimental phenomena
can be observed/explained, are enumerated.
We have computationally yielded a (minimal) set of
molecular actions that can explain the particular cell
cycle kinetics and gene expression profiles of HSCs
under leukemia. Our results implicate on the molecu-
lar level that HSCs tend to be cancerized by the
stress of leukemia, but eventually they suppress the
functionality as self-protection. The results may pro-
vide pilot knowledge and additional insights to further
studies of leukemia-induced functional alterations of
hematopoietic cells. Meanwhile, our computational
modeling method can be generalized and serve for
other biological or biomedical studies.
Results
Gene expressions showed significantly differential profiles
of Maff and Egr3 in the progression of leukemia
As done in our previous research, we profiled the
gene expressions in BM HSCs (from control and
leukemia mice) at different time points (Day 7, Day
10 and Day 14) and screened the differentially
expressed genes [7, 8]. Since highly-expressed genes
were usually regarded as having biological import-
ance [14], we highlighted Maff and Egr3 as they were
among the most highly expressed (Fig. 1a) and their
functional roles in HSCs under leukemia were less
known [7, 8]. The high expressions of the two genes
in HSCs were validated using quantitative reverse-
transcription PCR (qRT-PCR) (Fig. 1b).
System modeling revealed the molecular interaction
mechanisms of Maff and Egr3 in HSC cell cycle
Although bioinformatic databases such as NCBI,
REACTOME, and KEGG suggested that Maff and
Egr3 collocate with several cell cycle components
(e.g. Cdk2, Cdk4/6, etc.) in low-level, specific func-
tional pathways involved in transcription regulations
of hematopoietic differentiation/development, they
did not include any knowledge about the molecular
mechanisms that how Maff or Egr3 influenced cell
cycle [15, 16]. Since systems biology implied that
components co-existing in a specific bio-pathway
were functionally coordinated [17], it could be fairly
assumed that there might be (direct or indirect)
functional relations between the two genes and the
cell cycle components. We systematically imple-
mented in silico tests on combinations of all possibil-
ities that Maff/Egr3 had positive, negative or no
actions at all, on the cell cycle components
(Additional file 7: Table S1), aiming to examine
Fig. 1 Differential expression profiles of Maff and Egr3 during leukemia progression. a According to microarray data, Maff and Egr3 are significantly
highly expressed under leukemia. Their expressions reach the highest levels at the late stage (≥ Day 14) of leukemia, which are shown herein.
The x- and y- axes are the log2 values of gene expression intensities in the microarray (leukemia and control, respectively); and the two red dashed lines
(parallel to the diagonal) represent expression levels that are of 2-fold changes comparing to control, which serve as conventional indicators for
significant changes in gene expression. b Relative expression levels of the two genes measured by qRT-PCR are shown. The data validate the high
expressions of the two genes in HSCs under leukemia
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which ways of actions formed a system structure that
gave rise to the particular kinetic phenomena
observed in experiments. We used the experimental
data of in vitro liquid culture, cell cycle flow cytome-
try and gene expressions of HSC cell cycle as
references [7]. From the in silico tests, we proved
that at least three molecular actions that “Maff − ⊣
p18”, “Egr3 − ⊣ Cdk2(:CyclinE)”, and “Egr3 − ⊣ Cdk4/
6(:CyclinD)” were necessary for the experimental
phenomena that (individual) transductions (i.e. over-
expressions) of Maff and Egr3 greatly accelerated and
suppressed HSC cell cycle (Figs. 2 and 3), as well as
the real expression levels of cell cycle regulators in
HSCs which both Maff and Egr3 were highly
expressed (Fig. 4). The three molecular actions
formed a minimum inference of the mechanisms that
Maff and Egr3 functionally influenced the HSC cell
cycle (Fig. 5, Additional files 1, 2, 3: Figure S1, S2,
S3, Additional file 7: Table S1). For other ways of ac-
tions, in clear contrast to Figs. 2, 3, 4, the system
structures they dictated could not generate the ob-
served kinetics; thus they were discarded as false
hypotheses in model selection (Additional file 4:
Figure S4). For details of methods, refer to Materials
and Methods and Additional file 6.
Model-based computational analyses of the dynamics of
Maff/Egr3- mediated alterations of HSC cell cycle under
leukemia
Based on the model structure endowed by the three mo-
lecular actions “Maff − ⊣ p18”, “Egr3 − ⊣ Cdk2(:CyclinE)”,
and “Egr3 − ⊣ Cdk4/6(:CyclinD)”, we can further explore
the regulatory mechanisms of Maff and Egr3 computa-
tionally. By dynamical analyses, we observed that the ex-
pression of Maff generated a bistable system state to
accelerate cell cycle only when Egr3 expression was low or
medium (Figs. 6a-c). On the other hand, when Egr3 was
highly expressed, no matter Maff expression was high or
low, cell cycle was not accelerated as the system could not
yield a bistability that increased the levels of the cell cycle
checkpoint-determinants (Figs. 6a-i). The results indicated
that although Maff and Egr3 had opposite regulatory ef-
fects on cell cycle, the inhibitory power of Egr3 was more
potent than the activatory ability ofMaff.
Fig. 2 Simulations of system dynamics with respect to Maff expression. a-c Stable equilibriums (steady states) of Cyc D*, Cyc E* and E2F with respect
to the expression level of Maff are shown in (a), (b) and (c) respectively. As known, the three molecules are benchmarks for the transitions of G0
- > G1/G1 - > S in cell cycle and their levels directly correspond to the speeds that cells proceed through the transition checkpoints. The data curves
consist of the steady state concentrations of the molecules under various genetic synthesis rates (ks_maff, i.e. expression level) of Maff. As shown
herein, steady states of Cyc D* a and E2F c have increased as ks_maff rises, indicating that G0 - > G1 is accelerated upon high expression of Maff. In
addition, Cyc E* b is maintained at a level that is capable of driving G1 - > S. Cyc D/E* means the activated forms of Cyclin D/E (i.e. being bound with
their corresponding Cdks). Metric units of x- and y- axes are “moles/cell/min” and “moles/cell”. d Proliferation of HSCs over-expressing (i.e. transducted
with) Maff is shown herein; “Vector” means cell transducted with an empty vector (i.e. control data). As shown, the proliferation capability of HSCs with
high expression of Maff is significantly larger (p-value <0.005 compared with control). e Ratio of HSCs staying in G0 phase before (control) and after
Maff transduction (over-expression). Cells in different cycling status are sorted using flow cytometry according to Ki67 and Hoechst 33,342 staining. Data
show that the ratio of G0 HSCs is significently lowered when Maff is highly expressed (p-value <0.05), indicating that high Maff expression mobilizes
HSCs to escape the G0 phase, thus more HSCs enter the later cycling phase(s)
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Validation of the molecular actions by analyses of gene
sequences
To further confirm the fidelity of the study and minify
the possibility of overfitting in modeling, for each dis-
covered molecular action (molecule X genetically acting
on Y), we validated it by examining if the gene sequence
of Y harbored any regulatory element on which the gene
product of X could act, or if there existed an (or more)
intermediate(s) Z, who could act on Y and harbored tar-
get regulatory elements of X at the same time.
As it was known that Maff possessed a conserved basic
region flanked by a heptad repeat motif (bZip), through
which the protein recognized a specific palindromic se-
quence TGCTGAC(G)TCAGCA (maf recognition elem-
ent, MARE) to mediate DNA binding and potentiate
gene transcription [18]. Since the p18 gene did not con-
tain MARE, we surveyed all known genes that contained
MARE in the promoter region (i.e. in a range of ~2kbp
upstream TSS, by convention). We identified that
Blimp1/Prdm1 contained MARE at the location of
156 bp upstream its TSS (Fig. 7a); meanwhile, Blimp1
was shown to repress p18 expression by various studies
[19, 20]. Furthermore, Blimp1 was also a transcription
factor of hematopoiesis functioning in differentiation of
blood cells, thus coherently relevant to cell cycle regula-
tion. In all, Maff could act as transcription factor on (i.e.
activate) Blimp1, and Blimp1 subsequently down-
regulated p18. Therefore, the acting relationship
“Maff − ⊣ p18” had been confirmed.
For Egr3, we carried out the similar gene sequence
survey to detect if it was functionally related with the
cell cycle regulators (Cdk2/4/6, Cyclin D/E). We identi-
fied that gene Anapc11 linked to a cis element
(CGCCCCCGC) which Egr3 could recognize and acti-
vate transcription (Fig. 7b). The product of Anapc11,
APC11, was a core catalytic subunit of the anaphase-
promoting complex/cyclosome (APC/C), which could
act on mitotic cyclins and greatly suppress the transition
of G0/G1 phase to S phase [21]. Since it was
CyclinD:Cdk4/6 and CyclinE:Cdk2 that governed the
phase transition G0/G1 → S and Egr3 could transcrip-
tionally activate APC11, it was a support for our infer-
ences that the acting relationships “Egr3 − ⊣
CyclinD:Cdk4/6” and “Egr3 − ⊣CyclinE:Cdk2” might
Fig. 3 Simulations of system dynamics with respect to Egr3 expression. a-c Stable equilibriums (steady states) of Cyc D*, Cyc E* and E2F with respect to
the expression level of Egr3 are shown in (a), (b) and (c) respectively. Similar to Fig. 2a–c, data are steady state concentrations under various genetic
synthesis rates (ks_egr3, i.e. expression level) of Egr3. Stable equilibriums of all the three cell cycle checkpoint-determining molecules have shifted downward
as ks_egr3 increases, especially for Cyc E* b and E2F c as their steady states decline sharply in the manner of bistability (i.e. low-level stable equilibriums
occur due to dynamical bifurcation; red lines). The steady states of Cyc D* exhibit very slight upward fluctuations at certain Egr3 expression levels because
the decreases in E2F at those ks_egr3 values result in less amounts of p18 and p19 (inhibitors of Cyc D*), thus causing the transient elevation. However, the
Cyc D* level rapidly declines as ks_egr3 further increases. Noteworthy, when ks_egr3 exceeds certain values, the three molecules are all suppressed to very
low levels, indicating that high Egr3 expression potently suppresses cell cycle. d Proliferation of HSCs over-expressing (i.e. transducted with) Egr3; similar to
Fig. 2d, “Vector” stands for control data. As shown, the proliferation capability of HSCs highly expressing Egr3 is significantly lowered (p-value <0.005). e Ratio
of HSCs staying in G0 phase before (control) and after Egr3 over-expression. Data show that the ratio of G0 HSCs is significently heightened when Egr3 is
highly expressed (p-value <0.05), indicating that high Egr3 expression arrests HSCs in the G0 phase, reducing the number of HSCs entering the later
phase(s) of cell cycle
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exist. In all validations, all molecules surveyed originated
from the same species as our study subject (mouse).
Mechanistic implications of high Maff and Egr3
expressions in hematopoietic molecular regulations
One would intuitively assume that since Maff stimulated
cell cycle (and thus proliferation) of HSCs, HSCs might
highly express it so as to adapt to the leukemic environ-
ment, where the surrounding malignant cells were highly
proliferative. It was no surprise that normal cells were
apt to be cancerized in a malignant environment, since
adaptation was an universal cellular behavior from
bacteria to higher organisms [22, 23].
However, the molecular mechanisms of why the
actions of Maff (“Maff⟶ Blimp1 − ⊣ p18”) were neces-
sary for the cancerization of HSCs, remained unclear. We
answered the question by depicting the hematopoietic mo-
lecular network of important transcription regulators with
our newly revealed knowledge (Fig. 8). In mammalian,
GATA-1 (encoded by gene Gata1) was recognized as a
master regulator at the upstream of hematopoietic differen-
tiation; it transcriptionally activated various downstream
regulators, including Cyclin D(1) and NF-E2/p45, the het-
erodimic functional partner of Maff [24, 25]. When Maff
was highly expressed and gained the regulatory power
upon activation of NF-E2/p45, it possibly activated tran-
scriptions of other downstream regulators like Blimp-1
(Blimp1), β1-tubulin (Tubb1). In addition, we also identi-
fied that PF-4 (Pf4), another downstream regulator, har-
bored at its gene promoter region the transcription factor
recognition motif for Maff (Additional file 5: Figure S5).
In fact, these were all differentiation-promoting transcrip-
tion regulators that were ought to be activated at later
stages of HSC differentiation in normal condition [3, 26].
On the other hand, the suppression of p18 by (high expres-
sion of) Maff breaks the negative feedback control on
Cyclin D(:Cdk4/6), which amounts to a great up-
regulation of Cyclin D activity. Since Cyclin D is the
Fig. 4 Simulations of gene expression activities of cell cycle components. a-b Genetic synthesis rates, which are proportional to the transcription rates
of genes, are computed herein as surrogates for gene expression activities. Simulation data of Cyclin D, Cyclin E, Cdk2 and Cdk4/6 (a) and multiple CKIs
(b) under the circumstance that Maff and Egr3 are both highly-expressed (Maff+, Egr3+) are shown. Subtypes of cyclins are not distinguished in modeling
in order for simplifying computation (i.e. Cyclin D1, D2 and D3 are taken altogether as one molecule Cyclin D; E1 and E2 are taken together as E). In the
labels, “Gene.Exp.” means gene expression, “~” means equivalency or proportionality. c-e: Experimental measurements of relative expressions of the
cyclins (c), Cdks (d) and CKIs (e) when Maff and Egr3 are both highly-expressed (Maff+, Egr3+; i.e. Day 14 of leukemia). Data are obtained by qRT-PCR; and
it is shown that the simulation results are consistent with experimental data in terms of expressions of all CKIs, Cdks and Cyclins. Since the modeling
does not distinguish molecular subtypes, simulation of Cyclin D expression amounts to the overall level of all subtypes, which is also consistent with the
sum of D1, D2 and D3 in the experimental data
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initiating regulator of cell cycle, thus high expression of
Maff accelerates the overall cell cycle. Therefore, for sake
of sufficiently accelerating cell proliferation, high expres-
sion of Maff became necessary for both transcriptionally
repressing the CKI and potentiating the downstream regu-
lators, as a means of adapting to the malignant
environment.
The functional role of Egr3 was more clear. It had
already been experimentally revealed that Egr3 up-
regulated p18 and p19 expressions [7]. However, al-
though the two CKIs biochemically inhibited the activity
of Cyclin D(:Cdk4/6), we computationally discovered the
inhibitions alone were not sufficient for potent suppres-
sion of cell cycle (Additional file 4: Figure S4A-C). To
realize the largely-increased G0 ratio of HSCs as experi-
mentally observed (Fig. 3e), it was necessary that Egr3
genetically suppressed CyclinD:Cdk4/6 and Cycli-
nE:Cdk2. Therefore, it could be fairly supposed that Egr3
was highly expressed to suppress cell cycle to fullfil the
cellularity controlling principles when proliferations or
demands for resources exceeded certain limits. Based on
the above, we preliminarily explained why the two func-
tionally opposite genes Maff and Egr3 were both highly
expressed in the leukemic environment (especially at the
late stage, i.e. ≥ day 14).
Discussion
In our previous study, we identified that Maff and Egr3
were two highly-expressed genes which were important
to hematopoiesis and had opposite functional influences
on (BM) HSC cell cycle. However, the molecular mecha-
nisms of how they mediate the cell cycle alterations
remain unrevealed. By utilizing bioinformatics resources
and systems biology approaches, we summarized all
database-registered molecular relationships and identi-
fied the (minimal set of) molecular actions that lead to
the very experimentally-observed cell cycle kinetics and
gene expressions, via testing all possible hypothese of
molecular actions (i.e. model selection) in a curated
mammalian cell cycle kinetic model [11–13]. We have in
silico demonstrated that the three regulatory relation-
ships we identified are at least required, the experimen-
tal observation cannot be reproduced without any one of
them (Additional file 4: Figure S4).
It is interesting to ponder why the two functionally
opposite genes are both highly expressed in leukemia.
Since Maff stimulates cell cycle by down-regulating p18,
its high expression is possibly resulted from adaptation
to the malignant environment (i.e. cancerization), in
which leukemic cells rapidly proliferate. However, we
sample the normal HSCs from a non-irradiated animal
model, thus their normal physiological/biophysical prop-
erties (i.e. controlling mechanisms of cellularity) are kept
[7]. Therefore, although they have the ability of adapta-
tion, these HSCs cannot become completely cancerous
after all. Hence, it is fairly assumed that when prolifera-
tions or demands for resources exceed certain limits,
cells forcibly shut down functionalities to fullfil the
cellularity controlling principles. Since overexpression of
Egr3 potently suppresses cell cycle (Fig. 6), it is possibly
a “harsh control” measure that HSCs employ in
leukemic environment.
Furthermore, the relativity of Maff/Egr3 functions for
HSC cell cycle can only be screened with a non-
irradiated (i.e. un-manipulated) leukemia model, as
intact HSCs without overt damages (e.g. immune system
destruction) can be measured during leukemia progres-
sion. On the contrary, given the typical pre-conditioned
leukemia models utilized in most of previous studies,
the physiology of native leukemogenesis is destroyed, i.e.
non-leukemic cells in the leukemic host are no longer
the “normal” cells because they are heavily damaged by
the myeloablative manipulations and thus deviant far
from the normal cellularity [7, 9, 27–30]. Gene expres-
sions in those study designs (other than ours) cannot
represent in vivo functions; hence if in those cases,
Maff/Egr3 regulations on HSC cell cycle could not have
been inferred.
In our previous research, we found that in leukemic
BM, the HPC count increased and the rate that HSCs
Fig. 5 Molecular regulatory system of cell cycle (G0→ G1/G1→ S).
Since the HSCs in which Maff and Egr3 are highly expressed
(i.e. functional) are mainly G0-phase cells (over 90%), it implicates that if
Maff and Egr3 have influence(s) on cell cycle, they must exert influence(s)
in G0→ G1/G1→ S in the first place. Therefore, as a preliminary at-
tempt, we summarized all key regulators in G0→ G1/G1→ S (including
two cyclins, five CKIs, Rb, E2F and Akt) and examined all possible ways
that Maff and Egr3 (highlighted in red) act on the molecular network
that result in consistent phenomena with experimental observations.
Symbols: “−⊣” - inhibition; “―→” - activation; solid lines - transcriptional
regulations; dashed lines - biochemical interactions; red lines:
computionally inferred molecular regulatory relationships mediated by
Maff and Egr3
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differentiate into HPCs was high at the beginning; mean-
while, the differentiation of HSCs towards HPCs was
almost shut off later and the HPC count decreased
acutely after day 14 [9]. Furthermore, significantly
increased quiescence of HSCs was observed at the late
stage of leukemia [7]. These cellular-level results render
a hint that HSCs respond to leukemia with a process of
cancerization/self-protection. When leukemia emerges,
HSCs accelerate their cell cycles to proliferate into more
functional blood cells to compensate cell loss; on the
other hand, as leukemic cells become dominant and out-
grow normal cells, most HSCs stay in the quiescent
state, which is far less sensitive to environmental affects
[7, 9, 31, 32]. Here in this study, by revealing how Maff
and Egr3 act on cell cycle, we find the trait of “canceriza-
tion/self-protection” on the molecular level. Thus this
pilot finding may enhance the suggested mechanism and
provide a further explanation for the response of HSCs
to leukemic environment.
In methodology, we assembled bioinformatic resources
of molecular interactions and refined them by kinetic
modeling to acquire pilot knowledge. As bioinformatics
generates likelihoods and kinetic modeling provides ex-
planations for mechanisms, our approach presented
Fig. 6 Dynamic simulations of Maff and Egr3-mediated alterations of cell cycle. a-c Steady states of Cyc D* (a), Cyc E* (b) and E2F (c) with respect
to ks_maff under medium Egr3 expression level (low < ks_egr3 < high) are shown herein. In this circumstance, higher Maff expression is able to
uplift the levels of Cyc D*, Cyc E* and E2F, resulting in bistability in their steady states (red lines). Dynamics of the three molecules under low Egr3
expression level (with respect to ks_maff) are equivalent to Fig. 2a-c, in which high expression of Egr3 is not presumed (ks_egr3 = low). d-f Steady
states of Cyc D* (d), Cyc E* (e) and E2F (f) with respect to ks_maff under high Egr3 expression level (ks_egr3 = high). In this circumstance, increase
in Maff expression (ks_maff) is unable to effectively uplift the steady states of Cyc D*, Cyc E* and E2F any more. g-i Steady states of Cyc D* (g),
Cyc E* (h) and E2F (i) with respect to ks_egr3 when Maff expression level is high (ks_maff = high). The situation is similar to those of Fig. 3a - c
(ks_maff = low), in which high Egr3 expression potently suppresses the steady-state levels of all three molecules. The results indicate that no
matter Maff expression is high or low, cell cycle is suppressed when Egr3 is highly expressed
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herein sets a preliminary model for the combined efforts.
Such a practice is worthwhile to be generalized and
extended for further utilities.
Conclusion
Previous studies have shown that functions of normal
HSCs are altered in leukemic environment. Unexpect-
edly, two genes Maff and Egr3 that are originally
regarded as functioning mainly in somewhere else rather
than HSCs, are important for the functional alteration.
Moreover, the two genes oppositely function on cell
cycle but they are both highly expressed under leukemia.
Due to the interest to study the functional alteration of
HSCs as well as the difficulty for in vivo experiments,
we combine computational and experimental
approaches to investigate the genes’ acting mechanisms
on cell cycle. We have identified three potential molecu-
lar regulations and the results indicate that HSCs tend
Fig. 7 Validation of the molecular interactions by sequence analysis. a According to our survey of gene sequences, p18 does not harbor the direct
recognition element (i.e. binding motif) of Maff in its transcription promoter region; therefore, we check if there is any intermediate that both contains
that motif (in the promoter region) and can negatively regulate p18. We have found that Blimp1/Prdm1, which is also a transcription factor in the
regulation of hematopoietic differentiation, harbors the Maff binding motif in its promoter region; and the motif is 156 bp upstream the transcription
start site (TSS). Meanwhile, Blimp1/Prdm1 can transcriptionally repress p18 in regulation of the cycling of hematopoietic cells. Thus the transcription
regulatory relation “Maff ―→ Blimp1 − ⊣ p18” is indicated, and our computational inference “Maff − ⊣ p18” is well supported. b Our survey has also
identified that Anapc11, which is a core coding gene of the anaphase-promoting complex/cyclosome (APC/C) that inhibits mitotic cyclins and greatly
suppresses G0→ G1/G1→ S, links to the cis element that Egr3 recognizes and exerts transcription activation (523 bp upstream the TSS). Therefore, it
implies that “Egr3 ―→ Anapc11” and “Anapc11 −⊣ Cyclin D/Cdk4/6, Cyclin E/Cdk2”; thus our computational inference that “Egr3 − ⊣ CyclinD:Cdk4/6,
CyclinE:Cdk2” is supported
Fig. 8 Molecular regulations of cell cycle and hematopoiesis. GATA-1 (Gata-1) activates the cell cycle components as well as p45 NF-E2, the heterodimer
partner of Maff. The Maff:p45 NF-E2 functional complex is self-regulated and it activates the transcriptions of various downstream regulators, e.g. Blimp-1
(Blimp1), β1-tubulin (Tubb1), and PF-4 (Pf4). Altogether with our prediction that “Maff − ⊣ p18”, it can be concluded that high expression of Maff eliminates
the feedback inhibtion of p18 to Cyclin D:Cdk4/6, as well as up-regulating the downstream TFs. Hence, cell cycle will be accelerated and proliferation/
differentiation of hematopoietic cells are enhanced. This is why we hypothesize that high expression of Maff adapts cells to a rapidly proliferative status,
i.e. cancerization. On the other side, Egr3 suppresses the checkpoint controllers of G0→ G1/G1→ S and activates CKIs, thus its high expression greatly
inhibits cell cycle. Thus it is fairly assumed that it may be a “harsh control” via which HSCs forcibly shut down functionalities when their behaviors exceed
the limits of cellularity controlling principles, i.e. self-protection
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to adapt to the malignant environment but eventually
shut down the functionality to stay in the dormant state.
These results may provide insights for future studies;
and moreover, our combined use of experimental/com-
putational efforts is also applicable to other studies and
inspires interdisciplinary research methods.
Methods
Experimental animal model of AML
The non-irradiated mice models of leukemia and control
were established according to the protocols described in
the previous work [7]. All mice were maintained in the
animal facility and samples of BM HSCs (CD45.1+LKS+)
were extracted from both leukemia and control mice at
different time points (days: 0, 7, 10 and 14) for further
measurements.
Microarray analysis
Microarray of gene expressions in the CD45.1+LKS+
cells was performed at CapitalBio in Beijing. Procedures
for total RNA extraction, cRNA amplification, labeling,
and hybridization, as well as RNA quality confirmation,
were implemented according to protocols that we de-
scribed previously [7, 8]. Raw data normalization and
analysis of differentially-expressed genes were done
using Microarray Analysis Software v5.0 (Affymetrix).
Quantitative reverse-transcription PCR (qRT-PCR)
Total RNA was isolated using Qiagen RNeasy mini kit.
cDNA was synthesized using Improm-II™ reverse tran-
scriptase (Promega) or SuperScrip™ III (Invitrogen).
qRT-PCR was carried out with primers/probes that
were previously specified [7, 8]. qRT-PCR was
performed on 7500 or StepOne real-time PCR system
(Applied Biosystems).
Flow cytometry
HSCs were flow sorted by gating on Lin− Sca-1+ c-Kit+
(LKS+) of the CD45.1+ cells from the BM sample of our
mouse model. Cell cycle states of HSCs (LKS+) were rec-
ognized by the marker of cytoplastic protein Ki67 and
addition of DNA dye Hoechst33342. Cells in G0 phase
were gated on Ki67− Hoechst−; cells in G1 phase were
gated on Ki67+ Hoechst−; and cells in S/G2/M phase
were gated on Ki67+ Hoechst+. All antibodies (Abs) used
herein were from BD Biosciences or e-Bioscience; and
all experimental procedures were implemented accord-
ing to the protocols that we specified previously [7].
Transduction of HSCs
The Maff and Egr3 cDNAs were purchased from
Origene and HSCs (CD45.1+LKS+) were transfected with
retroviruses containing plasmids constructed with the
Maff and Egr3 cDNAs or an empty segment (control).
Plasmid construction and retroviruse production were ac-
cording to protocols previously described [7, 8]. Cells were
pre-cultured for 1 day, then transfected with retroviruses
(Maff, Egr3 or control) and incubated for another 2 days.
The culture was maintained in StemSpan SFEM medium.
After transduction, GFP+ cells were sorted for assays.
In vitro liquid culture
1000 transduced cells (with Maff, Egr3 or control; GFP+)
were sorted into 16 wells of a 96-well plate per group,
cultured in SFEM medium. Cell numbers were counted
every 2 days after day 6 using flow cytometry.
Bioinformatic resources of molecular interactions
Data of molecular interactions and functional pathways
were referenced from public databases of NCBI, REAC-
TOME, and KEGG. Genes/proteins associating with
Egr3 and Maff as well as collocating with them in spe-
cific functional pathways of hematopoietic cell cycle reg-
ulations were surveyed as potential targets that Maff and
Egr3 acted on cell cycle. So far as G0 → G1/G1 → S
were considered, there were three molecules, namely,
Cdk2/CyclinE, Cdk4/6/CyclinD, and p18. Respectively,
Maff was potentially associated with Cdk2/CyclinE and
p18; and Egr3 was suggested to be associated with Cdk2/
CyclinE and Cdk4/6/CyclinD.
Kinetic modeling of cell cycle (G0 → G1/G1→ S)
Ordinary differential equations (ODEs) were used to
model all the genes’ dynamics in terms of expression
levels. First-order Hill function was utilized to describe
both regulations of gene transcription and protein
activity. We considered the expression levels of
Cdk2(:CyclinE), Cdk4/6(:CyclinD) and E2F to be the
controlling benchmarks, because their expression
levels were nearly invariant in cell cycle [13]. We also
considered the coupling of cell cycle with cell apop-
tosis and survival (mediated by p53 and AKT, respect-
ively). Parameters from various references were
collected [12, 13, 33–38], in which transcription rates
were scaled to the benchmarks. For all ODEs, their for-
mulas were shown in Additional file 6 and values of
parameters were listed in Additional file 8: Table S2.
Model selection
We assumed that Maff and Egr3 might have positive,
negative or no actions at all, on their respective associat-
ing cell-cycle-related genes or proteins. We systematic-
ally implemented in silico tests on all combinations of
the possibilities, which were 34 = 81 combinations in
total (Additional file 7: Table S1). For each combination
(Ωi, i = 1,2,…,81) specified by possible ways that Maff
and Egr3 acted on Cdk2/CyclinE, Cdk4/6/CyclinD and
p18, i.e.
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Ωi ¼ Maff →i1 Cdk2;Maff →i2 p18;Egr3→i3 Cdk2; Egr3→i4 Cdk4=6f g
ik∈ positive;negative; nof g; k ¼ 1; 2; 3; 4ð Þ
the in silico test was simulating the dynamic states of the
integrated model (Mi) comprised by the cell cycle model
and Ωi (see Additional file 6 for details). We checked if
the simulation results were consistent with the experi-
mental observations of cell proliferation (in vitro liquid
culture), G0-phase proportion (cell cycle flow cytometry)
and cell-cycle-related gene expressions. Based on the tests,
we could see which ways of actions formed a system
structure that gave rise to the particular phenomena
observed in experiments. These molecular actions were
regarded as rational predictions and used for further
analyses; the rest were discarded as false hypotheses.
Dynamic simulation
With an initial value in the normal range of molecular
quantity level [13, 33, 36–38], we obtained the time-
courses of molecular quantities by numerically solving the
ODEs (Additional file 6 and Additional file 8: Table S2).
We used the Gear method so as to alleviate the stiffness
problem of ODEs [39]. For comparison with experimental
observations, stable equilibriums of (dynamic) system
states must be computed, since it was the equilibriums,
not the transient states in the midst of time-courses, were
correspondent to experimental observations that could be
stably measured (i.e. states that the system could steadily
reside). If a system had equilibrium(s), its time-course tra-
jectories tend to some area(s) over adequately large ranges
of time and parameter spaces. And if it did not, trajector-
ies spread out (usually traversing several orders of magni-
tudes). To locate the equilibrium, we utilized the state at
the end time point of the time-course as an initial guess
and used the trust-region method [40]. The stability of the
equilibrium was defined following the concept of
Lyapunov theory [41]. For an equilibrium, eigenvalues of
the Jacobian matrix (shown below) evaluated at it were
examined. If all eigenvalues had negative real parts, the
equilibrium is (asymptotically) stable; if any of them had a
positive real part, the equilibrium is unstable.
JXeq ¼
∂ A⋅R X;Pð Þð Þ
∂X
 
X¼Xeq
Gene sequence analysis
Sequence alignment was employed to detect whether
a given gene harbored a TF-binding element. We
adopted the most stringent criterion to require that
all nucleotides must be matched so that the identifi-
cation of an element was accounted. Such a practice
might help avoid ambiguity in the standard of identi-
fication and filter out positive false results. Moreover,
we only consider nucleotide segments in the range of
2kbp upstream from the TSS to be the positive iden-
tification of a regulatory element for a gene. All gene
sequences surveyed herein were referenced from the
NCBI Gene database.
Additional files
Additional file 1: Figure S1. Regulatory network with edge “Maff→
Cdk2 (:Cyclin E)”. Another possible regulatory model includes an additional
positive regulation on Cdk2/CyclinE by Maff, which is also capable of
reproducing the qualitatively correct dynamic profiles illustrated by the
experimental data (see Additional file 7: Table S1 for details). Here we do
not discriminate the correctness between the model shown in Fig. 5 and
the alternative one herein, as both models are qualitatively valid given the
current data. The minimal model shown in Fig. 5 is chosen as example due
to the principle of simplicity. (PNG 31 kb)
Additional file 2: Figure S2. Simulation results with additional regulation
“Maff→ Cdk2 (:Cyclin E)” with respect to Maff. Dynamics with respect to the
transcription rate of Maff at high (upper), medium (middle), and low (lower)
Egr3 expression-levels. In each panel, steady-state molecular quantities of
Cyclin D-Cdk4/6 (left), Cyclin E-Cdk2 (middle) and E2F (right) are shown. The
correct bistability with respect to Maff is qualitatively reproduced with the
additional molecular action. (PNG 73 kb)
Additional file 3: Figure S3. Simualtion results with additional regulation
“Maff→ Cdk2 (:Cyclin E)” with respect to Egr3. Dynamics with respect to the
transcription rate of Egr3 at high (upper) and low (lower) Maff expression-
levels. In each panel, steady-state molecular quantities of Cyclin D-Cdk4/6
(left), Cyclin E-Cdk2 (middle) and E2F (right) are shown. The correct bistability
with respect to Egr3 is qualitatively reproduced with the additional molecular
action. (PNG 31 kb)
Additional file 4: Figure S4. Outcomes produced by other regulatory
sturctures. Apparently false dynamics resulted by other hypotheses of
regulations. Basically, all the other network structures than the one in Fig. 5/
Additional file 1: Figure S1 produce qualitatively false results on (at least) one
of Cdk4/6:CyclinD, Cdk2:CyclinE, and E2F. Here we show the most typically
false results, combinations of regulatory relations are randomly assigned.
Upper panel: unrealistic dynamic levels of Cdk2:CyclinE and E2F with respect
to Maff transcription under low Egr3 expression, which is dictated by a
randomly assigned network structure (regulatory code 1212); middle panel:
results of Cdk2:CyclinE and E2F dictated by another network structure
(regulatory code 2133); results of Cdk4/6:CyclinD and E2F dictated by a third
different network structure (regulatory code 3321). Refer to Additional file 7:
Table S1 for depiction of the regulatory codes. (PNG 52 kb)
Additional file 5: Figure S5. Binding motif of Maff is also discovered
within 2 kb upstream of Pf4 gene. The Maff binding motif for transcriptional
activation occurs at a location <1 kb upstream the transcription start site
(TSS) of Pf4, which is potentially within the promoter region of the gene.
The observation indicated that Maff might positively regulate Pf4, which is a
regulator of platelet formation. (PDF 5 kb)
Additional file 6: Formulations of the mathematical model. Descriptions
for the ODEs and the modeling process are enclosed here. (DOC 128 kb)
Additional file 7: Table S1. Table for the combinatorial numerical tests.
Qualitative results of the numerical tests on combinations of possible
regulatory relations are documented here, with all 81 combinations
exhausted. The first four columns represent the regulatory code, “1” –
inhibitory, “2” – none, and “3” – activatory effects, respectively. Molecular
actions are indicated by the column headers. The last two columns show
the agreement or discrepancy with input experimental data, “0”
qualitative discrepancy, “1” qualitative agreement. The input experimental
data for model training are the cell-cycle status after transduction of
Maff/Egr3 and qRT-PCR results for cell-cycle genes. (XLSX 13 kb)
Additional file 8: Table S2. Model parameters. Symbols, definitions,
values, units and references for all model parameters are listed in the
table here. (XLS 28 kb)
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